Complete Remission in a Patient with Treatment Refractory Bullous Pemphigoid after a Single Dose of Omalizumab

Bullous pemphigoid (BP) is an autoimmune disorder known to be mediated by immunoglobulin G (IgG) autoantibodies. The role of immunoglobulin E (IgE) antibodies is being investigated as their presence has been described in severe cases. Herein, we report a patient of BP who was refractory to most conv...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Surabhi, Agrawal, Diksha, Sardana, Kabir, Kulhari, Anita, Malhotra, Purnima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413437/
https://www.ncbi.nlm.nih.gov/pubmed/32832453
http://dx.doi.org/10.4103/idoj.IDOJ_438_19
_version_ 1783568796174254080
author Sinha, Surabhi
Agrawal, Diksha
Sardana, Kabir
Kulhari, Anita
Malhotra, Purnima
author_facet Sinha, Surabhi
Agrawal, Diksha
Sardana, Kabir
Kulhari, Anita
Malhotra, Purnima
author_sort Sinha, Surabhi
collection PubMed
description Bullous pemphigoid (BP) is an autoimmune disorder known to be mediated by immunoglobulin G (IgG) autoantibodies. The role of immunoglobulin E (IgE) antibodies is being investigated as their presence has been described in severe cases. Herein, we report a patient of BP who was refractory to most conventional agents and developed hypotension after rituximab but achieved lasting remission after a single dose of the anti-IgE monoclonal antibody omalizumab.
format Online
Article
Text
id pubmed-7413437
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-74134372020-08-20 Complete Remission in a Patient with Treatment Refractory Bullous Pemphigoid after a Single Dose of Omalizumab Sinha, Surabhi Agrawal, Diksha Sardana, Kabir Kulhari, Anita Malhotra, Purnima Indian Dermatol Online J Case Report Bullous pemphigoid (BP) is an autoimmune disorder known to be mediated by immunoglobulin G (IgG) autoantibodies. The role of immunoglobulin E (IgE) antibodies is being investigated as their presence has been described in severe cases. Herein, we report a patient of BP who was refractory to most conventional agents and developed hypotension after rituximab but achieved lasting remission after a single dose of the anti-IgE monoclonal antibody omalizumab. Wolters Kluwer - Medknow 2020-07-13 /pmc/articles/PMC7413437/ /pubmed/32832453 http://dx.doi.org/10.4103/idoj.IDOJ_438_19 Text en Copyright: © 2020 Indian Dermatology Online Journal http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Sinha, Surabhi
Agrawal, Diksha
Sardana, Kabir
Kulhari, Anita
Malhotra, Purnima
Complete Remission in a Patient with Treatment Refractory Bullous Pemphigoid after a Single Dose of Omalizumab
title Complete Remission in a Patient with Treatment Refractory Bullous Pemphigoid after a Single Dose of Omalizumab
title_full Complete Remission in a Patient with Treatment Refractory Bullous Pemphigoid after a Single Dose of Omalizumab
title_fullStr Complete Remission in a Patient with Treatment Refractory Bullous Pemphigoid after a Single Dose of Omalizumab
title_full_unstemmed Complete Remission in a Patient with Treatment Refractory Bullous Pemphigoid after a Single Dose of Omalizumab
title_short Complete Remission in a Patient with Treatment Refractory Bullous Pemphigoid after a Single Dose of Omalizumab
title_sort complete remission in a patient with treatment refractory bullous pemphigoid after a single dose of omalizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413437/
https://www.ncbi.nlm.nih.gov/pubmed/32832453
http://dx.doi.org/10.4103/idoj.IDOJ_438_19
work_keys_str_mv AT sinhasurabhi completeremissioninapatientwithtreatmentrefractorybullouspemphigoidafterasingledoseofomalizumab
AT agrawaldiksha completeremissioninapatientwithtreatmentrefractorybullouspemphigoidafterasingledoseofomalizumab
AT sardanakabir completeremissioninapatientwithtreatmentrefractorybullouspemphigoidafterasingledoseofomalizumab
AT kulharianita completeremissioninapatientwithtreatmentrefractorybullouspemphigoidafterasingledoseofomalizumab
AT malhotrapurnima completeremissioninapatientwithtreatmentrefractorybullouspemphigoidafterasingledoseofomalizumab

Ejemplares similares